Nuvation Bio Cancer Drug IBTROZI Hits 50-Month Response Milestone

IBTROZI Achieves 50-Month Response Duration in Lung Cancer Trial

Nuvation Bio (NYSE: NUVB) reported a significant clinical milestone for its cancer treatment, IBTROZI® (taletrectinib), on March 17, 2026. Based on an August 2025 data cutoff from its TRUST-I and TRUST-II studies, the drug achieved a median Duration of Response (DOR) of 50 months. This result, described by the company as demonstrating unprecedented durability, was observed in tyrosine kinase inhibitor (TKI)-naïve patients diagnosed with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).

Pivotal Data Set for Presentation at AACR 2026

The complete dataset is scheduled to be a central feature of Nuvation Bio's presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 17–22, 2026. The presentation will expand beyond the TKI-naïve cohort to include new efficacy and safety data for patients who have been previously treated with TKIs. This comprehensive data reveal positions taletrectinib as a potentially leading treatment in its class, drawing significant investor attention ahead of the April conference as the market anticipates the full clinical profile.